Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

reproductive medicine

- PMLiVE

FDA approves Ferring’s Adstiladrin as first gene therapy for bladder cancer

Non-muscle-invasive bladder cancer represents around 75% of all new bladder cancer cases

- PMLiVE

Ferring agrees Chinese reproductive medicine research deal

Work with the Chinese Academy of Sciences on the long-term project

- PMLiVE

NICE finally set to back wider use of Ferring’s Firmagon

And acknowledges drug's benefits for prostate cancer that spreads to the spine

Ferring signs telemedicine collaboration with Danish hospital

Will work with North Zealand University Hospital on IBD patient care

- PMLiVE

Ferring collaborates on novel IBD drug development

Project in partnership with Paris-based Institut Pasteur

- PMLiVE

Ferring’s Inna Demidova moves to ELC

Takes up Russia and CIS role at the regulatory affairs specialist

National Institute for Health and Care Excellence NICE logo

NICE gives partial backing to Ferring’s prostate cancer drug

Firmagon on course for use on NHS in England and Wales

- PMLiVE

Interview: Michel Pettigrew, Ferring

Ferring Pharmaceuticals' president on how the company encourages 'controlled entrepreneurship'

- PMLiVE

Ferring appoints Novartis’ Alex Chang

He will lead the pharma company’s Asia Pacific business

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links